Change the trajectory of metabolic health
Virta helps organizations lower healthcare costs by delivering measurable, lasting health outcomes for their members. Members lose weight with or without GLP-1s, reverse type 2 diabetes, and reduce medication dependence.
Transformative outcomes that last
Members can see meaningful improvements within weeks, with outcomes sustained over time.
Meaningful Weight Loss
31 lbs
Our members experience weight loss similar to that delivered by current weight-loss drugs¹
Sustained Results After GLP-1
85%
Sustained weight loss a year after GLP-1 deprescription²
Cost Savings
$6,000 PMPY
Reversing metabolic conditions leads to massive savings³
One integrated solution for metabolic health
Choose the programs that fit your population, from nutrition-first weight loss and responsible GLP-1 care to diabetes management and reversal. Every program is built to deliver measurable outcomes that last.
Virta for
Weight Loss
Deliver clinically meaningful weight loss and prediabetes reversal without GLP-1s
Virta for
Weight Loss +
Nutrition-first care paired with appropriate GLP-1 use and a proven path to lasting results
Virta for
Diabetes Reversal
Safely deprescribe diabetes medications and return blood sugar to subdiabetic levels
Virta for Diabetes Management
Monitor and control blood sugar, provide app-based educational content, and a path to reversal
With or without GLP-1s, Virta delivers the clinical support members need to lose weight, reverse type 2 diabetes, and lower overall healthcare costs
Learn about our approach to GLP-1s
How the Virta partnership works
ROI Analysis
Everything starts here. We’ll provide a cost-savings estimate based on information you provide about your population’s current metabolic health
Choose products
Based on your analysis, we’ll help decide if focusing on weight loss, GLP-1s, diabetes, or a combination is right for your organization
Contracting & member enrollment
After we agree on goals, our focus will shift to making sure as many of your people take advantage of Virta as possible
Results
As your population starts to enroll, we’ll give you updates on progress and how the metabolic health of your population is changing
Why organizations choose Virta
Easy contracting
From quick turnaround deployments through your Health Plan to complex and customized solutions, Virta takes the workload off of your team.
Shared risk
We put 100% of our fees at risk when delivering health outcomes for your population. If the metrics outlined during contracting aren’t met, you don’t pay.
Transparent results
We report on enrollment marketing performance, share health updates for your population, recommend how to get the most out of your partnership with us.
Available to 12M+ employees at leading organizations
Proven and validated
By addressing the underlying metabolic condition, Virta improves health far beyond diabetes and obesity, leading to positive change for your population.
Life-saving Impact
56%
Lower incidence of heart attack, stroke, and death4
Depression Improvement
29%
Fewer people meeting the clinical cutoff for depression5
Knee Pain Reduction
56%
People with clinically meaningful knee pain improvement6
Improved Kidney Health
43%
Reduction in new onset of stage 3 chronic kidney disease7
Liver Disease Prevention
62%
Lower risk of a new diagnosis
of advanced liver disease,
including MASH8
Decreased Inflammation
39%
Reduction in hsCRP, with improvements across 19 of 21 markers9
Frequently asked questions
Get in touch with a Virta expert
Connect with a Virta expert about how your organization can improve metabolic health, reduce medication dependency, and lower healthcare costs.
Our approach supports members across obesity, prediabetes, type 2 diabetes, sustainable weight loss, and GLP-1 care.
Citations and Footnotes
- Hallberg SJ, McKenzie AL, Williams PT, et al. Effectiveness and safety of a novel care model for the management of type 2 diabetes at 1 year: an open-label, non-randomized, controlled study. Diabetes Ther. 2018;9(2):583-612. doi:10.1007/s13300-018-0373-9.
- McKenzie AL, Athinarayanan SJ. Impact of glucagon-like peptide 1 agonist deprescription in type 2 diabetes in a real-world setting: a propensity score matched cohort study. Diabetes Ther. 2024;15(4):843-853. doi:10.1007/s13300-024-01547-0.
- Virta Health. Actuarial analysis based on clinical trial results. Published 2021. Trended 2 years using 6.5% for medical costs and 8.8% for prescription drug costs. Savings model available upon request.
- Roberts CGP, Shanmugam PV, Athinarayanan SJ, et al. Cardiovascular outcomes among adults with type 2 diabetes or obesity receiving carbohydrate-reduced nutrition via telemedicine: a retrospective claims-based cohort study. Accepted for publication, 2026. Final journal citation pending.
- Adams RN, Athinarayanan SJ, McKenzie AL, et al. Depressive symptoms improve over 2 years of type 2 diabetes treatment via a digital continuous remote care intervention focused on carbohydrate restriction. J Behav Med. 2022;45(3):416-427. doi:10.1007/s10865-021-00272-4.
- Lyman KS, Athinarayanan SJ, McKenzie AL, et al. Continuous care intervention with carbohydrate restriction improves physical function of the knees among patients with type 2 diabetes: a non-randomized study. BMC Musculoskelet Disord. 2022;23(1):297. doi:10.1186/s12891-022-05258-0.
- Athinarayanan SJ, Bjornstad P, Shanmugam PV, et al. Effectiveness of Telehealth Low-Carbohydrate Intervention in Preventing Chronic Kidney Disease: A Real-World, Retrospective, Matched Cohort Study. Diabetes Obes Metab. 2026;28(10):9054-9068. doi:10.1111/dom.71086.
- Athinarayanan SJ, Wolfberg AJ, Shanmugam PV, Hameed BA, Bonacini M. Reduced risk of liver-related events among patients receiving individualized nutrition-focused remote care in the United States Hepatology. 2026;84(3):870-885. doi:10.1097/HEP.0000000000001713
- Athinarayanan SJ, Phinney SD, et al. Broad-Spectrum Effects of Carbohydrate Reduction on Inflammatory and Immune Mediators in Type 2 Diabetes. Endocr Res. 2026 May;51(2):100-116. doi: 10.1080/07435800.2026.2659579.